Eurofins Enhances Clinical and COVID-19 Testing Offering in Japan Through Acquisition of Genetic Lab Co.,Ltd.
10 Dezembro 2021 - 3:30AM
Business Wire
Eurofins Scientific (EUFI.PA), the global scientific leader in
bioanalytical testing and a leader in clinical diagnostics testing,
announces a share purchase agreement with Transgenic Inc. (2342:JP,
Tokyo stock exchange) to acquire Genetic Lab Co.,Ltd. (“G Lab”), a
molecular biology based testing provider for diagnostics, biomarker
development and drug discovery. The acquisition will further
enhance Eurofins’ expansion in Asia and complement its global
network of clinical diagnostics laboratories focused on specialised
and advanced genetic testing.
G Lab employs over 70 staff and generated revenues of over EUR
13m in the financial year ending March 2021. Initially established
as a genetics technology based bio venture in 2000, G Lab has
developed a reputation among clinical communities in Japan for the
CAP accredited quality services provided by its technical experts,
in-house medical pathologists and cytotechnologists. G Lab also
provides diversified testing services supporting biomarker
development for companion drugs. Since Mar 2020, G Lab has played
an important role in the COVID-19 response in Japan, by
facilitating PCR testing, and supporting Hokkaido prefecture and
Sapporo city with their COVID-19 testing programmes
Through this acquisition, the Eurofins network will further
strengthen its position in the Japanese market, where it is
currently the market leader in environment testing and non-invasive
prenatal testing, by extending its service offering in BioPharma
services and clinical testing in Japan, notably increasing its
COVID-19 testing product and service offering to support the fight
against the pandemic.
Notes to Editors:
For more information, please visit
www.eurofins.com.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network
of 900 laboratories in over 50 countries, Eurofins’ companies offer
a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211209006048/en/
Investor Relations Eurofins Scientific SE Yuya Kusunoki +32 2
766 1620 ir@eurofins.com
Eurofins Scientific (EU:ERF)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Eurofins Scientific (EU:ERF)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
Notícias em tempo-real sobre Eurofins Scientific SE da Euronext bolsa de valores: 0 artigos recentes
Mais Notícias de Eurofins Scient.